Efficacy and Underlying Mechanism of Berberine Against Atherosclerosis: A Meta-Analysis in Preclinical Animal Studies

被引:2
作者
Jia, Dongdong [1 ]
Zhang, XinYue [1 ]
Guo, Qianqian [1 ]
Yang, Rui [1 ]
Yu, Haitao [2 ]
Zhao, Mengzhu [1 ]
Shi, Liu [1 ]
Liu, Menghua [1 ]
Wu, Aiming [1 ]
Zhang, Dongmei [1 ]
机构
[1] Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med, Minist Educ & Beijing, Beijing 100700, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathophysiol,Key Lab,Minist Educ Neurol Diso, Wuhan, Peoples R China
关键词
Berberine; atherosclerosis; preclinical studies; meta-analysis; mechanisms; CHOLESTEROL; HDL; COMPLEMENT; EXPRESSION; PREVENTION; MODELS; GUT;
D O I
10.1097/FJC.0000000000001308
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerosis is the primary cause of many cardiovascular diseases, and an increasing number of studies have shown that berberine could delay plaque formation and development. Therefore, we aimed to evaluate its effects and explore its mechanisms in this meta-analysis. We searched PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and VIP databases for original preclinical studies to conduct meta-analysis. Twelve articles (16 studies; 312 ApoE(-/-) mice) were included, and all the studies scored 3-5 points according to SYRCLE's risk of bias tool. Berberine could significantly decrease plaque area and plaque macrophage content (plaque area, SMD = -2.02, 95% CI: -2.80 to -1.24, P = 0.000; plaque macrophage content, SMD = -4.28, 95% CI: -7.67 to -0.88, P = 0.013); lower the levels of TC, triglyceride, and low-density lipoprotein (TC, SMD = -1.47, 95% CI: -2.20 to -0.74, P = 0.000; triglyceride, SMD = -0.77, 95% CI: -1.21 to -0.33, P = 0.000; low-density lipoprotein, SMD = -0.61, 95% CI: -1.11 to -0.11, P = 0.000), and change the secretion of inflammatory cytokines (IL-1 beta, SMD = -2.29, 95% CI: -3.40 to -1.18, P = 0.000; interleukin-6, SMD = -1.48, 95% CI: -2.11 to -0.85, P = 0.008; tumor necrosis factor-alpha, SMD = -1.98, 95% CI: -3.01 to -0.94, P = 0.000; interleukin-10, SMD = 1.78, 95% CI: 0.76 to 2.80, P = 0.015), but there were no significant differences in high-density lipoprotein levels and plaque lipid content (high-density lipoprotein, SMD = 0.02, 95% CI: -0.35 to 0.40, P = 0.021; plaque lipid content, SMD = -6.85, 95% CI: -21.09 to 7.39, P = 0.007). The results were robust across a range of sensitivity analyses. Therefore, the results indicate that berberine is a promising drug for the treatment of atherosclerosis through regulating lipid metabolism, inflammation, and plaque composition. However, some potential mechanisms remain to be further elucidated.
引用
收藏
页码:476 / 488
页数:13
相关论文
共 54 条
[11]   SYRCLE's risk of bias tool for animal studies [J].
Hooijmans, Carlijn R. ;
Rovers, Maroeska M. ;
de Vries, Rob B. M. ;
Leenaars, Marlies ;
Ritskes-Hoitinga, Merel ;
Langendam, Miranda W. .
BMC MEDICAL RESEARCH METHODOLOGY, 2014, 14
[12]  
Jawién J, 2004, J PHYSIOL PHARMACOL, V55, P503
[13]   Berberine increases adipose triglyceride lipase in 3T3-L1 adipocytes through the AMPK pathway [J].
Jiang, Dongqing ;
Wang, Dianhui ;
Zhuang, Xianghua ;
Wang, Zhanqing ;
Ni, Yihong ;
Chen, Shihong ;
Sun, Fudun .
LIPIDS IN HEALTH AND DISEASE, 2016, 15
[14]   Importance of HDL Cholesterol in Atherothrombosis: How Did We Get Here? Where Are We Going? [J].
Jose Badimon, Juan ;
Santos-Gallego, Carlos G. ;
Badimon, Lina .
REVISTA ESPANOLA DE CARDIOLOGIA, 2010, 63 :20-35
[15]   Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials [J].
Ju Jianqing ;
Li Jingen ;
Lin Qian ;
Xu Hao .
PHYTOMEDICINE, 2018, 50 :25-34
[16]   Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century? [J].
Keen, Helen I. ;
Krishnarajah, Janakan ;
Bates, Timothy R. ;
Watts, Gerald F. .
EXPERT OPINION ON DRUG SAFETY, 2014, 13 (09) :1227-1239
[17]   Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins [J].
Kong, WJ ;
Wei, J ;
Abidi, P ;
Lin, MH ;
Inaba, S ;
Li, C ;
Wang, YL ;
Wang, ZZ ;
Si, SY ;
Pan, HN ;
Wang, SK ;
Wu, JD ;
Wang, Y ;
Li, ZR ;
Liu, JW ;
Jiang, JD .
NATURE MEDICINE, 2004, 10 (12) :1344-1351
[18]   Effect of Intestinal Flora on Protein Expression of Drug-Metabolizing Enzymes and Transporters in the Liver and Kidney of Germ-Free and Antibiotics-Treated Mice [J].
Kuno, Takuya ;
Hirayama-Kurogi, Mio ;
Ito, Shingo ;
Ohtsuki, Sumio .
MOLECULAR PHARMACEUTICS, 2016, 13 (08) :2691-2701
[19]   Berberine promotes the development of atherosclerosis and foam cell formation by inducing scavenger receptor A expression in macrophage [J].
Li, Ke ;
Yao, Wenqi ;
Zheng, Xiudan ;
Liao, Kan .
CELL RESEARCH, 2009, 19 (08) :1006-1017
[20]   Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome [J].
Li, Xingxing ;
Su, Chunyan ;
Jiang, Zhibo ;
Yang, Yuxin ;
Zhang, Yue ;
Yang, Mengxia ;
Zhang, Xiumin ;
Du, Yu ;
Zhang, Jin ;
Wang, Li ;
Jiang, Jiandong ;
Hong, Bin .
NPJ BIOFILMS AND MICROBIOMES, 2021, 7 (01)